🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524715-37-00
Authorised Phase I

A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors

2025-524715-37-00 · tracked via the Priya Life Science EU tracker
Sponsor
Ideaya Biosciences Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Diagnosis
Decision date
08/09/2026
Enrollment target
73
Sites
Spain, France

Condition studied

MTAP-Deleted Advanced Solid Tumors

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524715-37-00 on CTIS ↗ ← All trials in the EU